Sales Nexus CRM

SS Innovations to Showcase SSi Mantra Robotic System at SRS 2026, Highlighting Telesurgery and Global Expansion

By Advos
SS Innovations International will present its SSi Mantra surgical robot at the Society of Robotic Surgery 2026 Annual Meeting, featuring a live kidney telesurgery from India and underscoring the platform's growing clinical adoption with over 12,375 procedures completed.
SS Innovations to Showcase SSi Mantra Robotic System at SRS 2026, Highlighting Telesurgery and Global Expansion

SS Innovations International Inc. (NASDAQ: SSII) is set to exhibit its SSi Mantra surgical robotic system at the Society of Robotic Surgery (SRS) 2026 Annual Meeting, scheduled for July 23-26 in Hollywood, Florida (https://ibn.fm/FkgsY). The company announced that the platform will be featured in multiple technical sessions, including a live robotic telesurgery broadcast from India, where a partial nephrectomy will be performed remotely, demonstrating the system's remote surgical capabilities.

Chairman and CEO Dr. Sudhir Srivastava will participate in conference presentations covering telesurgery, robotic surgery adoption, and regulatory developments. As of July 6, 2026, more than 12,375 procedures have been completed using the SSi Mantra system, encompassing cardiac, pediatric, and telesurgical procedures. Approximately 2,100 physicians have been trained on the platform, which has been used across over 170 different surgical procedures.

This showcase at one of the largest annual gatherings of robotic surgery specialists highlights SS Innovations' expanding clinical experience and growing focus on remote surgical capabilities. The company's presence at SRS 2026 signals its intent to increase global adoption of its technology, particularly in regions where access to specialized surgical care is limited.

The implications for the healthcare industry are significant. Telesurgery could revolutionize surgical care by enabling expert surgeons to perform procedures remotely, reducing the need for patient travel and expanding access to specialized care. For investors, the demonstration of live telesurgery and the growing procedure volume may indicate increasing market acceptance and potential for revenue growth. The company's progress in training physicians and expanding the range of procedures suggests a broadening addressable market.

SS Innovations continues to build its clinical evidence base, which is critical for regulatory approvals and adoption in new markets. The SRS 2026 event provides a platform to showcase these advancements to key opinion leaders and potential partners.

Advos

Advos

@advos